The spindle assembly checkpoint plays a pivotal role in preventing aneuploidy and transformation. Many studies demonstrate impairment of this checkpoint in cancer cells. While leukemia is frequently driven by transformed hematopoietic stem and progenitor cells (HSPCs), the biology of the spindle assembly checkpoint in such primary cells is not very well understood. Here, we reveal that the checkpoint is fully functional in murine progenitor cells and, to a lesser extent, in hematopoietic stem cells. We show that HSPCs arrest at prometaphase and induce p53-dependent apoptosis upon prolonged treatment with anti-mitotic drugs. Moreover, the checkpoint can be chemically and genetically abrogated, leading to premature exit from mitosis, subsequent enforced G1 arrest, and enhanced levels of chromosomal damage. We finally demonstrate that, upon checkpoint abrogation in HSPCs, hematopoiesis is impaired, manifested by loss of differentiation potential and engraftment ability, indicating a critical role of this checkpoint in HSPCs and hematopoiesis.
INTRODUCTION
Hematopoietic stem cells (HSCs) undergo self-renewal and differentiation to ultimately provide all cells of the blood system. They mostly sustain a quiescent state in the G0 phase of the cell cycle in vivo during which cellular and metabolic activities are held to a minimum level. Upon activation, HSCs enter the cell cycle to initiate self-renewal or differentiation. However, every round of DNA replication, due to increased metabolism and proliferation, might be associated with the generation of DNA lesions (Walter et al., 2015) . Most of the time DNA damage is detected and efficiently repaired. Lesions that remain unresolved, however, might be converted into and thus fixed in the genome as mutations or chromosomal aberrations such as translocations. This might result in the deregulation of HSCs and ultimately their leukemic transformation (Holyoake et al., 1999) .
As HSCs are mostly situated in the G0 state of the cell cycle, double-strand breaks are thought to be repaired primarily by the error-prone non-homologous end-joining pathway, which might result in an accumulation of genomic rearrangements (Mohrin et al., 2010) . Interestingly, HSPCs harbor DNA-damage-induced cell-cycle checkpoints and DNA repair mechanisms that differ from those usually found in differentiated tissues and cell lines in terms of activation, outcome, and efficiency. For example, HSCs and less primitive progenitors lack a proper G1/S checkpoint, which results in an inability of these cells to arrest at the G1/S boundary upon DNA damage . Furthermore, human HSPCs lack a decatenation checkpoint, which is usually responsible for the resolution of entangled chromosomes (Damelin et al., 2005) . Another crucial checkpoint ensuring genome integrity in somatic tissue is the spindle assembly checkpoint (SAC). The SAC forces an arrest at prometaphase until all chromosomes are correctly aligned to the mitotic spindle (Musacchio and Salmon, 2007) . It is thought to be an essential pathway to prevent translocations and aneuploidy, two hallmarks of cancer. There are some indications that hematopoietic progenitor cells arrest in G2/M phase when treated with the spindle drug nocodazole (Rohrabaugh et al., 2008) . Furthermore, a recent study showed that fetal HSCs isolated from mice with trisomy (a known consequence of an abrogated SAC) display severe engraftment deficits. Similar problems occurred upon serial transplantation of bone marrow (BM) cells hypomorphic for the SAC component BubR1 (Pfau et al., 2016) . In addition, a recent report demonstrated the requirement of the SAC for satellite cells, suggesting a general relevance of this mechanism for adult stem cells (Kollu et al., 2015) . Strikingly, multiple studies report a SAC malfunction in leukemic cells that is linked to the accumulation of translocations and aneuploidies. Leukemia is frequently driven by transformed HSPCs (Schnerch et al., 2013) . Given the important role of the SAC for the genetic integrity of somatic tissues and the implications of checkpoint failure in leukemia, it is somewhat surprising that it is actually not known in detail whether the SAC is actually active in HSPCs, and if so, whether it differs A B (legend on next page) mechanistically from the SAC in differentiated tissue and how it might contribute to genomic stability and regulation of hematopoiesis.
RESULTS

Inhibition of Proper Spindle Assembly Induces a G2/M Arrest and p53-Dependent Apoptosis in HSPCs
Prolonged treatment of proliferating somatic cells with anti-mitotic drugs induces a G2/M arrest by activation of the SAC followed by the induction of apoptosis via p53-dependent and -independent mechanisms (Bacus et al., 2001; Zhang et al., 2002) . To determine the mitotic checkpoint response in HSPCs, low-density bone marrow (LDBM) cells, containing HSPCs and differentiated cells isolated from C57BL/6 mice were incubated with cytokines to allow for their activation and entry into the cell cycle. They were subsequently treated with the spindle toxins nocodazole, taxol or, as a control, the solvent DMSO. Cell-cycle position, progression, and apoptosis of distinct types of HSPCs as well as more differentiated cells was determined by flow cytometry at various time points post drug induction. After treatment with cytokines alone (control), HSPCs and especially HSCs were predominantly detected in S phase. When treated with cytokines in conjunction with spindle drugs, HSPCs arrested at the G2/M boundary, whereas their S-phase content was strongly reduced. This effect was observed in lineage-negative cells (LinÀ), Lin-cKit+ (LKs), Lin-Sca1+cKit+ cells (LSKs or early progenitor cells), and HSCs but in a slight manner also in differentiated hematopoietic cells (Lin+). Whereas a strong G2/M arrest could be observed shortly after treatment with spindle drugs (4 hr), especially in HSPCs, elevated apoptosis did not appear before 24 hr of treatment. Furthermore, the more primitive HSPC subpopulations (HSCs and LSKs) showed a higher percentage of cells undergoing apoptosis compared with differentiated cells, implying an elevated sensitivity of these types of cells to spindle drugs. High levels of apoptosis were also detected in cells in S phase in all of the analyzed cell populations, but not before 24 hr (Figures 1B, S1A, and S1B). Interestingly, differentiated (Lin+) cells were not significantly affected by spindle drug treatment in terms of cell death. This behavior is not linked to their general lower cycling frequency, as exposure to additional cytokines effectively enhanced replication activity but not apoptosis ( Figure S1C ). As expected, treatment of unstimulated HSPCs solely with spindle drugs did not induce apoptosis, indicating that quiescent and non-cycling cells do not depend on microtubule dynamics ( Figure S2A ). We conclude that cycling HSPCs activate G2/M arrest in response to mitotic spindle failure. The data also reveal that apoptosis is only initiated upon prolonged treatment with spindle drugs and thus long-term (24 hr) activation of the checkpoint.
We next tested whether apoptosis upon mitotic arrest of HSPCs is p53-dependent. LDBM cells were again arrested at the G2/M boundary for 24 hr. Indeed, a significant reduction of apoptosis in all distinct HSPC subpopulations derived from p53 KO mice could be detected compared with wild-type (WT) cells when applying nocodazole. The observed reduction was even higher in response to taxol ( Figure S2B ). Apoptosis in response to prolonged mitotic arrest of HSPCs is thus, at least in part, p53-dependent.
The Mitotic Checkpoint Is Functionally Active in HSPCs
Upon activation of the SAC, many checkpoint kinases are active, such as Aurora B and MPS1. To further assess the functionality of the SAC in HSPCs, LDBM cells were driven into the cell cycle following a short exposure to taxol. Meanwhile, Aurora B or MPS1 kinases were inhibited by ZM447439 or reversine, respectively. In addition, some of these cells were also exposed to the proteasome inhibitor MG132 for 2 hr. As proteolysis is essential for triggering anaphase onset, MG132-treated cells should arrest even when the checkpoint is inactive. For mitotically arrested cells, phosphorylation of serine 10 or 28 in histone H3 (pH3) was assessed. In cells treated with taxol, a strong arrest in prometaphase could be observed, especially in LSKs and HSCs as judged by high rates of pH3 distribution. Treatment with taxol together with ZM447439 or reversine triggers loss of pH3 signaling, indicating checkpoint override and premature mitotic exit (Figures 2A, 2B , and S3A). Based on the chromatin shape of HSCs, the DNA of taxol and reversine/ZM447439-treated HSCs predominantly appeared decondensed, unlike cells treated only with taxol, harboring predominantly condensed nuclei ( Figure 2C , Movies S1 and S2). This mitotic exit in taxol/reversine/ ZM447439-treated HSPCs was suppressed by MG132, and cells remained pH3 positive and chromatin condensed, indicating an SAC override with the inability to initiate anaphase, as the function of the proteasome is necessary for chromosome segregation (Figures 2A-2C and S3A ). When treating cycling HSPCs solely with reversine, a strong checkpoint inhibition was observed as indicated by the reduced proportion of pH3 within the corresponding G2/M subpopulations. Furthermore, upon simultaneous treatment of these cells with reversine and MG132, a partial rescue of pH3 signaling could be seen ( Figure 2D ). To exclude that our inhibitors induce pH3 loss due to enhanced rates of apoptosis, HSPCs were treated as indicated and stained against the active (cleaved) form of caspase-3. Indeed, no significant or only moderate activation of caspase-3 could be observed ( Figure S3B ). Interestingly, when HSCs were treated with a combination of taxol and reversine, signs of re-initiation of DNA synthesis likely linked to tetraploidy could be observed based on 5-bromo-2-deoxyuridine (BrdU)/7AAD staining. As expected, especially P53-deficient HSCs presented with such a re-initiation of DNA synthesis. This effect was absent in LK cells, independent of the p53 status ( Figure S3C ). We also investigated the SAC in NIH/3T3 fibroblasts as a positive control. As anticipated, fibroblasts present with an active SAC. Upon treatment with various SAC inhibitors, we also observed minor signs of polyploidy ( Figures S3D-S3G ). Together, these data demonstrate that HSPCs as well as NIH/3T3 cells are able to mount a functional SAC.
Spindle Checkpoint Proteins Localize at Kinetochores
We next addressed the question whether the activation of the SAC in HSPCs correlates with the distribution of important checkpoint proteins to centromeres and kinetochores. The kinetochores are important catalyzing centers. Here, the mitotic checkpoint complex is formed, preventing anaphase progression (Musacchio and Salmon, 2007) . Some of the key SAC proteins are the Aurora kinases, which are distributed to the kinetochores and centromeres as a response to their phosphorylation upon activation (Vigneron et al., 2004) . HSPCs show high levels of phosphorylated Aurora at kinetochores upon treatment with spindle drugs in all cell populations analyzed, while this phosphorylation is almost absent in cells exposed to Ro3306, a CDK1 inhibitor that prevents mitotic entry (Figure 3A) . Other critical SAC proteins are BUBR1 and BUB1 (Musacchio and Salmon, 2007) . As expected, they both co-localize with active Aurora kinases in HSCs, LSKs, and less primitive progenitors during mitotic arrest, indicating proper activation of these proteins and appropriate SAC activity ( Figure 3B ).
A Proper Mitotic Checkpoint Is Required for Hematopoiesis
We next determined the consequences of a dis-functional SAC for hematopoiesis. As shown previously, downregulation of the SAC impairs the function of satellite cells and myoblasts, implying that a proper checkpoint is of general importance for adult stem cells (Kollu et al., 2015) . In order to test the role of impaired SAC activation in hematopoiesis, HSPCs were driven into the active cell cycle followed by addition of reversine or DMSO. After 24 hr of incubation, cells were used for the colony formation (CFU) assay to assess their differentiation ability. Indeed, SAC inhibition triggered a strong decrease in CFU frequency of HSPCs, with only few small colonies remaining upon reversine treatment ( Figure 4A ). Furthermore, reversine-treated donor cells showed a decreased engraftment ability at 4 weeks after transplantation, implying impaired function of HSPCs ( Figure 4B ). However, 12 weeks post transplant, both populations (treated and untreated) contributed similarly to chimerism. These data indicate that activation of (legend continued on next page) the SAC primarily impairs the proliferation of hematopoietic progenitors but less the function of HSCs, as early phases of engraftment mostly depend on committed progenitors, whereas engraftment at later time points is driven by more primitive cells (Busch et al., 2015) . Furthermore, no difference in the percentage of myeloid or lymphoid lineages in peripheral blood was observed, indicating that the differentiation potential of HSCs was not affected by the SAC inhibition ( Figure S4A ). Importantly, apoptosis can be excluded as a contributor to the observed impaired engraftment ( Figure S4B ). However, reversine induced a strong G0/G1 arrest in HSPCs ( Figures 4C and S4C) . A similar arrest was observed previously in satellite cells when genetically inhibiting the target of reversine, Mps1 (Kollu et al., 2015) . These results thus indicate that HSPCs harbor a safety mechanism arresting post-mitotic cells with a corrupted SAC in order to prevent potentially damaged cells from further cycling. Moreover, when treating cycling HSPCs as well as NIH/3T3 fibroblasts with reversine in conjunction with cytochalasin D to prevent cytokinesis, enhanced levels of chromosomal damage were observed, especially in fibroblasts and more committed progenitors but less in HSCs ( Figure 4D ). These data demonstrate that SAC abrogation indeed induces chromosomal damage, although mostly affecting less primitive BM cells and not HSCs directly. Expression of the SAC component BubR1 has been shown to be downregulated in BM cells in patients with acute myeloid leukemia, causing reduced SAC activity and decreased sensitivity to spindle drugs (Schnerch et al., 2013) . In addition, BubR1 hypomorphic BM cells present with an impaired engraftment ability upon serial transplantation (Pfau et al., 2016) . We tested the consequences of BubR1 deficiency on HSPC cell-cycle dynamics and hematopoiesis. In LDBM cells from BubR1 heterozygous mice (BubR1 À/À animals are embryonic lethal and die of apoptosis; Wang et al., 2004) we observe reduced BUBR1 protein expression ( Figure S4D ). Cycling HSPCs from these mice, when treated with taxol, resulted in a decrease in pH3 distribution compared with WT cells, particularly in HSCs and LSKs ( Figures 4E and S4E ). We conclude that HSPCs with only one BubR1 allele are not able to fully activate the SAC upon exposure to spindle drugs. However, cycling HSPCs treated correspondingly with DMSO or taxol isolated from WT or BubR1 +/À mice did not show any significant differences in the number of CFUs (granulocyte-macrophage progenitors) as well as CFU-E (erythroid progenitors) colonies, indicating that one BubR1 allele may still be capable of sustaining normal hematopoiesis with a partially active SAC ( Figure S4F) . Similarly, the absolute numbers in BM and cell-cycle characteristics of various progenitors, such as common lymphoid progenitors, LKs, and LSKs, but also HSCs obtained from BubR1 +/À mice, were similar compared with those for WT mice, indicating that partial loss of BubR1 affects hematopoiesis only to a small extent, as only LKs presented with a trend toward being more in S phase ( Figures 4F and 4G ). In addition, activated BubR1 +/À HSPCs do not exhibit enhanced levels of chromosomal aberrations after cell division compared with WT cells ( Figure S4G ). In summary, the mitotic checkpoint is active in HSPCs but might be only partially dependent on BubR1. A dysfunctional checkpoint affects primarily the function of progenitor cells but not more primitive types of cells such as HSCs directly.
DISCUSSION
Here, we demonstrate that murine HSCs and hematopoietic progenitors harbor a functional mitotic checkpoint. Actively cycling HSPCs in general and especially HSCs arrest at prometaphase when treated with spindle toxins followed by the induction of cell death after prolonged (24 hr) treatment with the drug. The SAC can be abrogated by inhibiting some of its key components, such as MPS1 and Aurora B, leading to premature mitotic exit and chromosomal abnormalities. We furthermore show that by inhibiting the checkpoint in proliferating HSPCs, hematopoiesis is partially corrupted as judged by decreased colony formation ability and impaired engraftment. HSPCs with only one BubR1 allele fail to sufficiently arrest at mitosis when exposed to taxol. Importantly, HSPCs from P53 KO mice do not exhibit high levels of apoptosis after extended treatment with spindle drugs. This finding is consistent with a loss of p53 as a critical driver of leukemogenesis (Wong et al., 2015) . However, anti-mitotic drugs also induce apoptosis in other cell-cycle phases besides G2/M in HSPCs. After prolonged treatment (24 hr), severe apoptosis was detected in S phase as well. Without the addition of cytokines, apoptosis was barely detectable. These observations could indicate that spindle drugs have side effects especially on cycling HSPCs, which warrant further investigation.
How does the SAC contribute to the maintenance of the HSPC pool to enable proper function of HSPCs and to quantifications. n = 3; 30-100 cells per sample were counted. Error bars are SEM with significances tagged with asterisks. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (E) LDBM cells isolated from BubR1 +/À or WT mice, respectively were treated with cytokines following treatment with taxol or the corresponding control, DMSO for 14 hr. Two hours before harvesting and processing for the analysis of the mitotic index, taxol-treated cells were further incubated with reversine or its control, DMSO. n = 4. *p < 0.05.
(legend continued on next page) prevent genomic instability and potentially transformation? DNA mutations are believed to be the major driver of HSC exhaustion in old mice (Dykstra et al., 2011) . For dormant or quiescent HSCs, a functional SAC would be of no great importance as cells are not cycling and mostly reside in G0. This is supported by our observation that non-cytokine-treated HSPCs do not show enhanced levels of apoptosis upon spindle drug treatment, even those in G2/M phase. Furthermore, BubR1 +/À HSCs do not show abnormalities in terms of cell-cycle distribution and absolute cell numbers, whereas LKs could be found to be more enriched in S phase and less in G2/M phase, although this difference was not significant. This indicates that, especially for HSCs from adult mice, BubR1 does not alter cell-cycle dynamics. These observations are supported by recent studies from Pfau et al. (2016) . Here, the authors used hypomorphic BubR1 BM cells for serial transplantation assays. Engraftment defects did not occur before secondary transplantation (Pfau et al., 2016) . Interestingly, when cycling HSPCs are treated with the checkpoint inhibitor reversine, chromosomal damage occurs and a durable G0/G1 arrest is induced. This could argue for a post-mitotic safety mechanism preventing checkpointabrogated HSPCs from further cycling. A similar pathway was described in satellite cells and, according to the authors, could contribute to genome integrity of stem cells (Kollu et al., 2015) . Our data also suggest that a functional SAC is more critical for committed progenitors than for more primitive compartments as indicated in our transplantation experiments. This assumption is supported by low numbers of chromosomal aberrations in HSCs upon reversine treatment. As steady-state hematopoiesis is primarily driven by progenitors and not by HSCs (Busch et al., 2015) , a functional SAC might be critical for hematopoiesis. A dysfunctional SAC might thus contribute to BM failure but also, in the long-run, genetic instability in HSPCs.
EXPERIMENTAL PROCEDURES
Mice C57BL/6 mice 8-16 weeks old were purchased by Janvier. p53 KO mice were developed previously and kept at the mouse facilities of the University of Ulm. BubR1 heterozygous mice developed previously were kindly provided by Darren J. Baker (Mayo Clinic, MA) and kept at the mouse facility of Cincinnati Children's Hospital Medical Center (CCHMC). All mouse experiments were performed in compliance with the German Law for Welfare of Laboratory Animals and were approved by the Regierungspräsidium Tübingen or the IACUC at CCHMC.
Cell Culture
For in vitro experiments, cells were cultured using IMDM medium supplemented with 1/100 GlutaMax (Gibco) in an incubator with 5% CO 2 at 37 C and normal oxygen conditions. HSCs were cultured using an incubator with 3% oxygen.
Statistical Analysis
Normal distribution of data was implied and the variance between the groups was similar. All statistical analyses were performed using Student's t test or two-way ANOVA when appropriate with GraphPad Prism 6 software. The number of biological repeats for every experiment (n) is mentioned in the figure legends. Error bars are SEM with significances tagged with asterisks: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. For detailed experimental procedures, please see Supplemental Information. 
SUPPLEMENTAL INFORMATION
CFU assay
CFU assays were performed as described previously (Xing et al., 2006) . Briefly, Lin-cells were plated in triplicate using 6-well plates (533 cells per well) and incubated for 7 days in methylcellulose medium (MethoCult® GF M3534, StemCell Technologies) with 5 % CO 2 at 37 °C. On day 7, colonies containing at least 50 cells were scored.
CFU-E assay
For the detection of erythroid progenitor cells (CFU-E colonies), 10 6 LDBM cells were similarly treated as for the CFU assay (without stimulation) described in the main text but MethoCult M3334 (StemCell Technologies) contained EPO was used instead. Two days after plating, colonies containing at least 8 cells were scored. subpopulations in BubR1 mice was performed as described previously (Guidi et al., 2017) .
Flow cytometry and cell sorting
LT-HSCs as well as the indicated progenitors were isolated as previously described (Florian et al., 2012 
Immunofluorescence analysis
Cell were harvested and fixed using BD Cytofix/Cytoperm solution for 20 min at 4°C.
Following a permeabilization step in PBS + 0.2% Triton X, cells were blocked in PBS containing 10% DNS. Primary antibodies were as follows: anti-Cleaved Caspase 3 (#9661,
Cell Signaling) at 1:400, anti-phospho Aurora kinases (#2914, Cell Signaling) at 1:100 and anti-phospho Serine10 Histone H3 (#9708S, Cell Signaling) at 1:250. Anti-BUB1 or anti-BUBR1 antibodies, provided by S. Taylor and produced as described previously (Taylor, Hussein et al., 2001 ) at 1:100, anti-Pericentrin (sc-28142) at 1:100 or anti-Tubulin (ab6160) at 1:1000. Following an incubation step for 1 h at RT, cells were washed twice and incubated using secondary antibodies (anti-mouse Alexa488, anti-rabbit Alexa546, anti-goat Alexa488, anti-sheep Alexa488 or anti-rat Alexa647; Jackson Immunoresearch) at a dilution of 1:1,000.
Before analyzing cells were mounted on glass slides using Antifade with DAPI solution (#P-36931, ThermoFisher). Imaging was performed using a Zeiss LSM 710 or a Observer.Z1 microscope. Western Blot 10 6 LDBM cells from BubR1+/-or WT mice were directly lysed in 100 µl 1xSDS sample buffer (60 mM Tris, 1% SDS, 8% Glycerol, 1.5% 2-Mercaptoethanol, 0.01% Bromphenol blue, pH 6.8). Following 5 min incubation at 95°C and 5 min sonification to shear genomic DNA, 10 µl were used for western blotting as described previously .
Transplantation
The indicated proteins were visualized using anti-BUBR1 (#ab28193, Abcam; 1:100) and anti-Actin (#A1978, Sigma-Aldrich; 1:1,000) antibodies. 2 nd HRP labeled antibodies were donkey-anti-mouse (sc-2914; 1:10,000) and donkey-anti-sheep (sc-2316; 1:10,000)
Quantification of BUBR1 levels were performed using ImageJ software.
